Read the latest reports on Western Europe, with local insight, sp...
Read the latest reports on Western Europe, with local insight, specialist knowledge and a comprehensive breakdown of key market data. Our research identifies key strategic themes relevant across the region, while also providing a more granular unders...
Dermatologicals has seen demand weaken in the post-pandemic period. While certain COVID-19 related habits, such as the use of hand sanitisers, remain relevant and people in Greece continue to use them much more than they did in the past, this is a…
Dermatologicals again registered positive current value growth in 2023, continuing the trend of the previous years. The most dynamic category – hair loss treatments – continued to post strong growth. There are several reasons supporting the demand…
Value growth for dermatologicals continues to slow in 2023 as local consumers prioritise the treatment of other health concerns. According to a study led by the French Society of Dermatology (SFD), one in three French citizen suffers from a skin…
Healthy growth in dermatologicals is stemming from launches of value-added products. There was a pause on most new product development activity during the COVID-19 crisis, but with the end of the pandemic, products that had been held back have been…
Dermatologicals is expected to register an increase in current value sales in 2023, partly as a result of the energy crisis stemming from the war in Ukraine, which is pushing up retail prices.
Sales of dermatologicals strongly rely on consumers visiting pharmacies (the dominant distribution channel) as Belgians rarely go first to these stores specifically to purchase such products. Instead these are generally secondary purchases alongside…
Dermatologicals is seeing mid-single digit growth in current value terms in 2023, although like many areas of consumer health this is largely the result of price increases. Prices have been rising across all categories of dermatologicals as a result…
Manufacturers have raised their prices due to the rising costs of energy, raw materials, production and logistics amid a highly inflationary climate. Nonetheless, in many cases, consumers have continued to buy the more expensive branded options as…
Current value sales of cough, cold and allergy (hay fever) remedies rebounded to pre-pandemic levels in 2022 as the UK experienced its strongest cold and flu season in recent years, as a result of greater socialising as restrictions eased, thereby…
Cough, cold, and allergy (hay fever) remedies is projected to continue to post retail current value growth in 2023, following a severe decline in 2020 due to the Coronavirus (COVID-19) pandemic. Having passed the 2019 pre-pandemic level in 2022, the…